Autophagy Activation Contributes to Glutathione Transferase Mu 1-mediated Chemoresistance in Hepatocellular Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jun 22

PMID 29928420

Citations 9

Authors

Xiu-Tao Fu

Kang Song

Jian Zhou

Ying-Hong Shi

Wei-Ren Liu

Meng-Xin Tian

Lei Jin

Guo-Ming Shi

Qiang Gao

Zhen-Bin Ding

Jia Fan

Affiliations

Soon will be listed here.

Abstract

Glutathione transferase Mu 1 (GSTM1) induces cancer drug resistance by hydrolyzing cancer chemotherapeutics or activating the anti-apoptosis pathway. However, the chemoresistance-inducing mechanism of GSTM1 in hepatocellular carcinoma (HCC) remains unknown. In the present study, the expression of GSTM1 was examined in three HCC cell lines. Oxaliplatin and sorafenib were selected as chemotherapeutic agents. Small interfering RNA was used to decrease GSTM1 expression. Cell death was measured using MTT and annexin V/propidium iodide assays. Activation of autophagy was evaluated by green fluorescent protein-light chain 3 redistribution and analysis of autophagy-related 5 expression in MHCC97-H and Huh-7 cells. A stepwise increase in GSTM1 expression with increasing metastatic potential of HCC cell lines was revealed. Cell death induced by oxaliplatin and sorafenib was significantly increased following GSTM1-knockdown in MHCC97-H and Huh-7 cells. Activation of autophagy was significantly inhibited by silencing GSTM1 expression. The results of the present study suggest that GSTM1 may protect HCC cells against the effect of oxaliplatin treatment through activating autophagy. The present study provides a novel perspective on HCC drug-resistance.

Citing Articles

Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications.

Lv N, Huang C, Huang H, Dong Z, Chen X, Lu C Antioxidants (Basel). 2023; 12(11).

PMID: 38001822 PMC: 10668987. DOI: 10.3390/antiox12111970.

Targeting and regulation of autophagy in hepatocellular carcinoma: revisiting the molecular interactions and mechanisms for new therapy approaches.

Hashemi M, Nadafzadeh N, Imani M, Rajabi R, Ziaolhagh S, Bayanzadeh S Cell Commun Signal. 2023; 21(1):32.

PMID: 36759819 PMC: 9912665. DOI: 10.1186/s12964-023-01053-z.

Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance.

Zhang J, Li Y, Zou J, Lai C, Zeng T, Peng J Front Oncol. 2022; 12:968547.

PMID: 35965498 PMC: 9366399. DOI: 10.3389/fonc.2022.968547.

Screening of molecular targets and construction of a ceRNA network for oxaliplatin resistance in colorectal cancer.

Wei W, Xi Y, Jiamin X, Jing Z, Shuwen H RSC Adv. 2022; 9(54):31413-31424.

PMID: 35527927 PMC: 9073375. DOI: 10.1039/c9ra06146k.

Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma.

Khaled J, Kopsida M, Lennernas H, Heindryckx F Cells. 2022; 11(4).

PMID: 35203283 PMC: 8870354. DOI: 10.3390/cells11040632.

References

Jin S, White E . Role of autophagy in cancer: management of metabolic stress. Autophagy. 2006; 3(1):28-31. PMC: 2770734. DOI: 10.4161/auto.3269. View

Hua L, Hu B, Yan D, Liu J, Shen Y, Zhao F . Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Pathol Res Pract. 2017; 213(6):688-697. DOI: 10.1016/j.prp.2016.11.014. View

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

Xu X, Liu R, Zhang X, Huang L, Chen F, Fei Q . DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther. 2012; 11(3):629-38. DOI: 10.1158/1535-7163.MCT-11-0531. View

Di Pietro G, Magno L, Rios-Santos F . Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol. 2010; 6(2):153-70. DOI: 10.1517/17425250903427980. View

Zhu Y, Zheng B, Wang H, Chen L . New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017; 38(5):614-622. PMC: 5457690. DOI: 10.1038/aps.2017.5. View

Mizushima N, Komatsu M . Autophagy: renovation of cells and tissues. Cell. 2011; 147(4):728-41. DOI: 10.1016/j.cell.2011.10.026. View

Shi Y, Ding Z, Zhou J, Hui B, Shi G, Ke A . Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy. 2011; 7(10):1159-72. DOI: 10.4161/auto.7.10.16818. View

Zaanan A, Williet N, Hebbar M, Dabakuyo T, Fartoux L, Mansourbakht T . Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2012; 58(1):81-8. DOI: 10.1016/j.jhep.2012.09.006. View

10.

Tian F, Deguchi K, Yamashita T, Ohta Y, Morimoto N, Shang J . In vivo imaging of autophagy in a mouse stroke model. Autophagy. 2010; 6(8):1107-14. DOI: 10.4161/auto.6.8.13427. View

11.

King F, Fong S, Griffin C, Shoemaker M, Staub R, Zhang Y . Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. PLoS One. 2009; 4(9):e7283. PMC: 2747272. DOI: 10.1371/journal.pone.0007283. View

12.

Gobel T, Blondin D, Kolligs F, Bolke E, Erhardt A . [Current therapy of hepatocellular carcinoma with special consideration of new and multimodal treatment concepts]. Dtsch Med Wochenschr. 2013; 138(27):1425-30. DOI: 10.1055/s-0033-1343232. View

13.

Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang S . MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer. 2014; 13:35. PMC: 3938074. DOI: 10.1186/1476-4598-13-35. View

14.

Tew K . Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54(16):4313-20. View

15.

Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y . Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. J Exp Clin Cancer Res. 2016; 35(1):159. PMC: 5045585. DOI: 10.1186/s13046-016-0430-z. View

16.

Ding Z, Hui B, Shi Y, Zhou J, Peng Y, Gu C . Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin Cancer Res. 2011; 17(19):6229-38. DOI: 10.1158/1078-0432.CCR-11-0816. View

17.

Yang T, Zheng Z, Li X, Li Z, Wang Y, Geng Y . MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood). 2013; 238(9):1024-32. DOI: 10.1177/1535370213497321. View

18.

Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T, Kuwano H . Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol. 2009; 16(3):761-71. DOI: 10.1245/s10434-008-0260-0. View

19.

Ding Z, Shi Y, Zhou J, Qiu S, Xu Y, Dai Z . Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res. 2008; 68(22):9167-75. DOI: 10.1158/0008-5472.CAN-08-1573. View

20.

Yang J, Luo Y, Qiu H, Tang W . Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line. Saudi Med J. 2009; 30(1):35-40. View